



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT

Friedman et al.

SERIAL NO.

08/599,974

EXAMINER:

Eileen B. O'Hara

FILED

February 14, 1996

ART UNIT

1646

FOR

DB, THE RECEPTOR FOR LEPTIN, NUCLEIC ACIDS

ENCODING THE RECEPTOR, AND USES THEREOF

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on January 30, 2003.

Betty Schultz
(Name of Depositor)

(Signature gate Bate)

RESPONSE TO NOTICE TO COMPLY

U.S. Patent and Trademark Office Box Sequence P.O. Box 2327 Arlington, VA 22202

Sir:

In Response to the "Notice to Comply" due February 2, 2003, Applicants enclose a paper and electronic copy of the Sequence Listing along with the Statement in Support of The Filing/Submission of a Nucleotide/Amino Acid Sequence Listing in Accordance With 37 CFR §1.821 - 1.825 and a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

No fees are believed to be necessitated by the foregoing amendments. However, should this be erroneous, authorization is hereby given to charge Deposit Account No. 11-1153 for any underpayment, or credit any overages.

Respectfully submitted,

CHRISTINE E. DIETZE Agent for Applicant(s)

Registration No. 37,309

KLAUBER & JACKSON 411 Hackensack Avenue Hackensack, NJ 07601 (201) 487-5800

Date: January 30, 2003

O 1 P E 'C'	Application No. 08/599,974	[₹] Äpplicant(s) Friedman et al.	
Notice to Comply	Examiner	Art Unit	
William of	Eileen B. O'Hara	1646	
NOTICE TO COMPLY WITH RI CONTAINING NUCLEOTIDE S DISCLOSURES			

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with

the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
∑ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other:
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For questions regarding compliance to these requirements, please contact:
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 PatentIn Software Program Support Technical Assistance
To Purchase Patentin Software 703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY